Physician profile
Christopher A Vanderneck
NPI 1366455974
$2,560.43
in general payments reported to CMS, 2019-2025
30 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $359 · 2021: $674 · 2022: $312 · 2023: $410 · 2024: $249 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $280.29 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $248.25 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $223.29 | 2019-2021 | |
| Pfizer INC. | $208.80 | 2019-2021 | |
| Astellas Pharma US INC | $188.09 | 2019-2024 | Veozah |
| Abbvie INC. | $179.12 | 2021-2025 | |
| Amgen INC. | $173.00 | 2019-2023 | Evenity, Prolia |
| Aimmune Therapeutics, INC. | $113.51 | 2024 | |
| Axsome Therapeutics, INC. | $103.16 | 2023-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.99 | 2019-2022 | |
| Allergan, INC. | $87.36 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.82 | 2020-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $70.96 | 2021-2025 | |
| Glaxosmithkline, LLC. | $68.99 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $65.40 | 2020-2024 | Gardasil 9, Gardasil |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $52.52 | 2020-2023 | Breztri |
| Xeris Pharmaceuticals, INC. | $48.15 | 2023 | Gvoke Hypopen |
| Medicure Pharma INC. | $47.65 | 2021 | |
| Seqirus USA INC | $34.40 | 2025 | Flucelvax, Fluad |
| Philips North America LLC | $26.85 | 2022 | |
| Genentech USA, INC. | $25.78 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.41 | 2022 | |
| Exact Sciences Corporation | $14.90 | 2025 | Cologuard Collection Kit |
| Pacira Pharmaceuticals Incorporated | $14.49 | 2023 | Iovera, Zilretta, Exparel |
| Kyowa Kirin, INC. | $14.26 | 2023 | Crysvita |
| Mylan Specialty L.P. | $13.98 | 2021 | |
| Dexcom, INC. | $13.12 | 2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $13.02 | 2023 | Eliquis |
| Ultragenyx Pharmaceutical INC. | $12.76 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Vanderneck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.